<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Clinical research FDA Special Protocol Assessment Center for Biologics Evaluation and Research Dendreon Cancer vaccine FDA Fast Track Development Program Food and Drug Administration Medicine Health |
Add to Reading List |
BLA Teleconference Summary - Provenge, June 26, 2007 | Microsoft Word - Savient press release Puricase SPAdocDocID: 1qW9f - View Document |
 | Microsoft Word - Savient Announces FDA Advisory PaneldocDocID: 1q0EW - View Document |
 | Microsoft Word - 9124dft.docDocID: 1ak2h - View Document |
![ACUSPHERE INC. REACHES SPECIAL PROTOCOL ASSESSMENT AGREEMENT WITH FDA FOR IMAGIFY™ PHASE 3 PLACEBO-CONTROLLED TRIAL LEXINGTON, MASS., June 8, [removed]Acusphere, Inc. (ACUS.PK), a specialty pharmaceutical company, today](https://www.pdfsearch.io/img/726a429d0812ff8145329035cf885f4b.jpg "ACUSPHERE INC. REACHES SPECIAL PROTOCOL ASSESSMENT AGREEMENT WITH FDA FOR IMAGIFY™ PHASE 3 PLACEBO-CONTROLLED TRIAL LEXINGTON, MASS., June 8, [removed]Acusphere, Inc. (ACUS.PK), a specialty pharmaceutical company, today") | ACUSPHERE INC. REACHES SPECIAL PROTOCOL ASSESSMENT AGREEMENT WITH FDA FOR IMAGIFY™ PHASE 3 PLACEBO-CONTROLLED TRIAL LEXINGTON, MASS., June 8, [removed]Acusphere, Inc. (ACUS.PK), a specialty pharmaceutical company, todayDocID: YRPF - View Document |
 | Microsoft Word - StarpharmadocxDocID: Wa8v - View Document |